Updated Jul 16, 2026
Pinkas Jan has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $23K.
Jan Pinkas is the Chief Scientific Officer at Crescent Biopharma, Inc., a biopharmaceutical company focused on developing novel therapeutics for solid tumors. He has been involved in the company's efforts to advance CR-001, a bispecific antibody aimed at improving cancer treatment outcomes.
| Role | Chief Scientific Officer |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-23 | CBIO | CRESCENT BIOPHARMA, INC. | S — Open-market sale | 1.3K | $17.99 | $23K |
Jan Pinkas is the Chief Scientific Officer at Crescent Biopharma, Inc., a biopharmaceutical company focused on developing novel therapeutics for solid tumors. He has been involved in the company's efforts to advance CR-001, a bispecific antibody aimed at improving cancer treatment outcomes.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($23K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Pinkas Jan profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.